Recent Security Class Actions

According to the Complaint, Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. In December 2019, the Company’s majority-controlled subsidiary, Avenue Therapeutics, Inc., which Fortress founded in 2015, submitted a New Drug Application for its intravenous Tramadol product to the U.S. Food and Drug Administration for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.